Терапевтический архив (May 2011)

Methotrexate-induced changes in the concentration of antibodies to modified citrulnated vimentin in blood serum of patients with rheumatoid arthritis

  • Natal'ya Petrovna Shilkina,
  • Mariya Sergeevna Voronina,
  • Aleksey Alekseevich Vinogradov,
  • Ol'ga L'vovna Borisova,
  • N P Shilkina,
  • M S Voronina,
  • A A Vinogradov,
  • O L Borisova

Journal volume & issue
Vol. 83, no. 5
pp. 10 – 13

Abstract

Read online

Aim. To study effects of methotrexate on the titer of antibodies to mutated citrullinated vimentin (anti-MCV) and ascertain possibility of using this marker for control of treatment results and choice of individual effective dose of the drug. Material and methods. A 12-month trial included 76 patients with verified rheumatoid arthritis (RA). Methotrexate per os was given in a dose 7.5-10 mg/week to 44(57.9%) patients, 25 patients received no basic therapy. Anti-MCV (IU/ml) were detected with commercial chemicals made in Germany (ORGENTEC). Results. RA patients given methotrexate doses 7.5 and 10 mg/week and untreated with basic anti-inflammatory drugs showed no significant differences by basic clinical and device parameters, level of anti-MCV at primary examination and 12 months later. Conclusion. Anti-MCV titer cannot be used for control of efficacy of methotrexate treatment in doses 75 and 10 mg/week, choice of individual effective doses.

Keywords